导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 2.47% | 1621/4773 |
| 近一周 | -2.53% | 2477/5462 |
| 近一月 | -4.98% | 2937/5421 |
| 近一季 | -8.83% | 2980/5209 |
| 近半年 | -6.61% | 3112/4920 |
| 近一年 | 7.28% | 1332/4366 |
| 近两年 | 69.32% | 988/2954 |
| 近三年 | 35.80% | 838/2253 |
| 成立以来 | 151.68% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
1.84% 1161/4961 |
18.31% 1393/5312 |
- - |
- - |
| 2025 | 30.80% 1287/4813 |
2.18% 1444/3635 |
1.99% 1967/4076 |
24.37% 1477/4524 |
0.92% 1662/4813 |
| 2024 | 6.20% 1781/3463 |
-2.55% 1378/2808 |
-5.20% 1670/3014 |
15.67% 1657/3129 |
-0.62% 1482/3463 |
| 2023 | -5.51% 747/2656 |
7.68% 536/2280 |
-3.88% 947/2385 |
-4.51% 1155/2515 |
-4.39% 1002/2655 |
| 2022 | -17.61% 609/2207 |
-13.22% 717/1919 |
3.17% 1202/2016 |
-10.37% 391/2113 |
2.67% 864/2208 |
| 2021 | 16.78% 259/1822 |
-1.38% 481/1255 |
9.43% 552/1330 |
4.76% 323/1466 |
3.29% 453/1822 |
| 2020 | 21.36% 691/1250 |
-4.69% 379/1028 |
16.67% 422/1067 |
6.47% 836/1164 |
2.52% 985/1184 |
| 2019 | 25.69% 595/1092 |
30.71% 234/754 |
-9.90% 701/804 |
0.49% 512/850 |
6.20% 642/918 |
| 2018 | -30.74% 474/834 |
- - |
- - |
- - |
-12.12% 405/691 |
| 2017 | 1.12% 455/714 |
- - |
- - |
- - |
- - |
| 2016 | -14.27% 336/605 |
- - |
- - |
- - |
- - |
| 2015 | 34.43% 62/575 |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 嘉实中证500ETF联接A VS. 长安沪深300非周期A(740101) |